Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 518 participants.
Also called NCT02926950
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 518 participants
- Sponsor
- Registry
-
NCT02926950 -
2016-001800-49
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Hungary, Slovakia
- Registry status
- Completed
Technical summary
Registry record NCT02926950. Randomized; double masking; primary purpose treatment. Start 2016-11 (actual); primary completion 2019-02-26 (actual). Results posted on 2021-05-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Sotagliflozin (SAR439954)
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Metformin
- Lead sponsor
- Lexicon Pharmaceuticals
- Collaborator
- Sanofi
Record details
- Record id
cardio:ct-nct02926950- Content hash
f4ce78dd9bf78f0be741c2771ffedffc83c69e3e1b20a6a7429a23b7f4cfb345